Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.61 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.60 |
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.57 |
| ▸ | GLP1R | P43220 | 9/20 | 0.56 |
| ▸ | GIPR | P48546 | 9/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119411 | 1.00 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL29707516 | 0.97 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL29707517 | 0.97 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL29707519 | 0.97 | C5AR1 (0.56) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL29707524 | 0.96 | C5AR1 (0.56) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL30644036 | 0.86 | GLP1R (0.63) | CXCR4GLP1RGIPR | |
| SCHEMBL31182499 | 0.86 | CXCR4 (0.60) | CXCR4GLP1RGIPRNPY1RNPY2R | |
| SCHEMBL29855927 | 0.86 | CXCR4 (0.66) | CXCR4GLP1RGIPRNPY1RNPY2R | |
| SCHEMBL38662670 | 0.85 | CXCR4 (0.62) | C5AR1TACR1CXCR4 | |
| SCHEMBL31703183 | 0.84 | GLP1R (0.69) | GLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299566-A1 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | BROWN UNIVERSITY | 2024-09-12 | — | — | US | disclosed |
| WO-2022150362-A1 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | MARSHALL JOHN (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299566-A1 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | PSD, BDNF, ARGLU1 | C5AR1 3791/4885IL23R 2128/4885TACR1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.